Maricann Group (CSE:MARI; OTCQB:MRRCF) announced a definitive agreement with Ontario pharmacy chain Lovell Drugs to become their exclusive medical cannabis product provider.
As quoted in the press release:
Lovell Drugs will, in partnership with Maricann, implement a medical cannabis education and access program for its pharmacists and allied community physicians that facilitates the counselling and fulfillment of medical cannabis to its patients. Maricann will fulfill prescriptions directly to Lovell Drugs’ patients through the existing Access to Cannabis for Medicinal Purposes Regulations. Lovell Drugs has already commenced distribution of Maricann cannabis products to its patients, with the first prescription registered and fulfilled on December 1st, 2017.
Lovell Drugs is a well established resource for community physicians and ideally positioned to educate and counsel patients on medical cannabis to help ensure appropriate access, education and clinical oversight. “Pharmacists’ expert understanding of polypharmacy equips them as the standard of care for all patients. We believe that our medical cannabis initiative to distribute cannabis directly to patients, with pharmacists as their primary source of counselling and information is the better way,” said Ben Ward, CEO of Maricann. “Until pharmacists are permitted to distribute cannabis products to patients directly, as is the case with all other pharmaceuticals, we believe this distribution model will provide an effective interim solution.”